Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
Status:
Active, not recruiting
Trial end date:
2021-12-03
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from
baseline values between peritoneal dialysis patients with hyperphosphatemia receiving
repeated administration of KHK7791 for 8 weeks and those receiving placebo.